Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
entrez:
25
10
2021
pubmed:
26
10
2021
medline:
13
1
2022
Statut:
epublish
Résumé
Use of stimulants continues to increase among older adults for a variety of indications. An association between stimulant use and increased risk of cardiovascular (CV) events has been established among children and young adults, but few studies have explored the risk of CV events among older patients, a group with increased baseline risk. To evaluate the association between stimulant use and risk of CV events among older adults. This propensity score-matched cohort study, with 4 nonusers per 1 user, was conducted from July 1, 2017, to June 27, 2019, using data from population-based health care databases from Ontario, Canada, from January 1, 2002, to December 31, 2016. Included individuals were outpatients aged 66 years or older. Initiation of a prescription stimulant. The primary outcome was a CV event, defined as a composite of emergency department visit or hospitalization for myocardial infarction, stroke or transient ischemic attack (TIA), or ventricular arrhythmia. Risk of CV event was assessed at 30 days, 180 days, and 365 days after initiation of stimulants from Cox proportional hazard models. A secondary analysis assessed each component of the primary outcome separately. Among 6457 older adults who initiated a prescription stimulant (ie, the exposed group) and 24 853 older adults who did not initiate such treatment (ie, the unexposed group), the distribution of baseline patient characteristics was well balanced after matching (sex: 3173 [49.1%] men vs 12 112 [48.7%] men; standardized difference, 0.01; median [IQR] age: 74 [69-80] years vs 74 [69-80] years; standardized difference, 0.01). Within this cohort, there were 932 CV events during the 365-day follow-up (5.11 events per 100 person-years among individuals who initiated stimulants). In the primary analysis, stimulant initiation was associated with increased risk of CV events at 30 days (hazard ratio [HR], 1.4; 95% CI, 1.1-1.8) but not at 180 days (HR, 1.2; 95% CI, 0.9-1.6) or 365 days (HR, 1.0; 95% CI, 0.6 to 1.8). In the secondary analysis, stimulant initiation was associated with increased risk of ventricular arrhythmias (HR, 3.0; 95% CI, 1.1-8.7) and stroke or TIA (HR, 1.6; 95% CI, 1.1-2.1) at 30 days. This cohort study found that stimulant use was associated with an early increase in CV events among older adults with no association for long-term use.
Identifiants
pubmed: 34694389
pii: 2785393
doi: 10.1001/jamanetworkopen.2021.30795
pmc: PMC8546494
doi:
Substances chimiques
Central Nervous System Stimulants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2130795Commentaires et corrections
Type : ErratumIn
Références
J Am Coll Cardiol. 2020 Aug 18;76(7):858-866
pubmed: 32792083
J Am Acad Child Adolesc Psychiatry. 2012 Feb;51(2):147-56
pubmed: 22265361
Case Rep Cardiol. 2016;2016:2343691
pubmed: 27579185
Case Rep Cardiol. 2016;2016:7967851
pubmed: 26998366
Mayo Clin Proc. 2001 Mar;76(3):323-6
pubmed: 11243281
BMJ. 2015 May 13;350:h2298
pubmed: 25972273
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Neuropsychiatr Dis Treat. 2014 Aug 22;10:1543-69
pubmed: 25187718
JAMA. 2011 Dec 28;306(24):2673-83
pubmed: 22161946
Am J Hosp Palliat Care. 2001 May-Jun;18(3):187-92
pubmed: 11406895
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
J Child Adolesc Psychopharmacol. 2014 Aug;24(6):302-10
pubmed: 24956171
Hypertension. 2009 Dec;54(6):1423-8
pubmed: 19858407
J Clin Psychopharmacol. 2018 Oct;38(5):505-508
pubmed: 30102629
Am J Psychiatry. 1995 Jun;152(6):929-31
pubmed: 7755127
Front Psychiatry. 2021 Apr 20;12:642798
pubmed: 33959050
BMJ. 2016 May 31;353:i2550
pubmed: 27245699
Cochrane Database Syst Rev. 2018 Aug 09;8:CD007813
pubmed: 30091808
N Engl J Med. 2011 Nov 17;365(20):1896-904
pubmed: 22043968
Eur Neuropsychopharmacol. 2013 Jun;23(6):534-41
pubmed: 22796229
MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):66-70
pubmed: 29346342
Arch Pediatr Adolesc Med. 2003 Jan;157(1):17-25
pubmed: 12517190
Pharmacoepidemiol Drug Saf. 2006 May;15(5):291-303
pubmed: 16447304
J Clin Hypertens (Greenwich). 2013 Feb;15(2):124-32
pubmed: 23339731
Am J Epidemiol. 2011 Jun 15;173(12):1404-13
pubmed: 21602301
Neuropsychiatr Dis Treat. 2016 Jan 08;12:79-87
pubmed: 26811680
Pediatrics. 2007 Dec;120(6):e1494-501
pubmed: 18055666
Clin Geriatr Med. 2009 Nov;25(4):563-77, vii
pubmed: 19944261
Can J Neurol Sci. 2016 Nov;43(6):765-773
pubmed: 27426016
BMJ. 2005 Apr 23;330(7497):960-2
pubmed: 15845982
JAMA. 2015 Nov 3;314(17):1818-31
pubmed: 26529160
Am J Psychiatry. 2015 Jun;172(6):561-9
pubmed: 25677354
Am J Psychiatry. 2012 Feb;169(2):178-85
pubmed: 22318795
J Urol. 2011 Oct;186(4):1340-4
pubmed: 21855905
Hosp Community Psychiatry. 1990 Dec;41(12):1330-3
pubmed: 1980482
J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921
pubmed: 17581453
JAMA Netw Open. 2019 Nov 1;2(11):e1914344
pubmed: 31675080
Am J Hosp Palliat Care. 2012 Sep;29(6):483-90
pubmed: 22144657
J Clin Psychopharmacol. 2008 Jun;28(3):296-301
pubmed: 18480686
Epidemiology. 2009 Jul;20(4):512-22
pubmed: 19487948
Am J Hosp Palliat Care. 2001 Nov-Dec;18(6):403-7
pubmed: 11712722
Pediatr Emerg Care. 1999 Aug;15(4):306
pubmed: 10460094
BMC Cardiovasc Disord. 2012 Jun 09;12:41
pubmed: 22682429
Int Psychogeriatr. 2014 Feb;26(2):239-46
pubmed: 24169147
JAMA Intern Med. 2021 May 1;181(5):707-709
pubmed: 33523100
Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):961-9
pubmed: 23813665
PLoS One. 2013;8(1):e52991
pubmed: 23382829
PLoS One. 2014 Jan 08;9(1):e84391
pubmed: 24416225